Best Oncology Companies in Italy
The 52 best Oncology companies in Italy in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NMS Group.
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Italy
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NMS Group Developer of therapeutics for the treatment of cancer | $158M | 54 mo ago | 1 | Nancy Selling Founder | WordPressMySQLPHP+21 | Acquired | — | — |
| 2 | Philogen Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $70M | 86 mo ago | 157 | Dario Neri Co-Founder | WordPressMySQLPHP+16 | Public | — | — |
| 3 | Genenta Science Developer of lentivirus-based gene and cell therapies for cancer | $34M | 16 mo ago | 9 | Pierluigi Paracchi Co-Founder Chairman And Chief Executive Officer | DrupalPHPAmazon Web Services+29 | Public | — | — |
| 4 | Sibylla Biotech AI-powered platform for drug discovery | $25M | 45 mo ago | 14 | Lidia Pieri Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+16 | Series A | 3 patents Patents concentrated in computing, sensing & instrumentation | — |
| 5 | BetaGlue Technologies Provider of a radiotherapy platform for the treatment of solid tumors | $19M | 25 mo ago | 14 | — | WordPressMySQLPHP+18 | Series A | — | — |
| 6 | Tethis Provider of automated solutions for in liquid biopsy 53Patents top 26%Growth top 28%Innovation top 29%Funding top 40% All 8 signals ▾Patentstop 26% Growthtop 28% Innovationtop 29% Fundingtop 40% Moattop 45% Globalbottom 42% Techbottom 38% Marketbottom 35% Patents: 57 patents matched (strict assignee match) · 16 filings since 2022 vs 11 in 2017-21 Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 18 mo ago | 32 | — | WordPressMySQLPHP+18 | Series A | 57 patents Sample preparation and immobilization devices for biochemical analysis and diagnostics | — |
| 7 | ViroStatics Early stage biotech developing antivirals (HIV and HPV) and onco drugs based on CDK Inhibitors | $13M | 107 mo ago | — | Franco Lori CEO | — | Series A | 3 patents Small‑molecule pyrimidine kinase inhibitors for therapeutic drug development | — |
| 8 | ALKemist Bio Developer of cellular immunotherapies for ALK-positive cancers | $8M | 31 mo ago | — | Roberto Chiarle Founder | — | Series A | — | — |
| 9 | IGEA Orthopedic medical devices to promote reparative osteogenesis and joint protection | $4M | 75 mo ago | 70 | Donata Marazzi CEO | — | Series A | 47 patents Patents concentrated in health & consumer products | 1 award |
| 10 | Haptena Developer of immunotherapies targeting genetically defined cancers for durable patient options | $4M | 7 mo ago | — | Chiara Ambrogio Co-Founder | — | Seed | — | — |
| 11 | Diatech Pharmacogenetics Provider of diagnostic kits for pharmacogenetic tests | $3M | 39 mo ago | 60 | — | Cart FunctionalityWordPressMySQL+35 | Late Stage | — | 1 job opening · 2 partnerships |
| 12 | Sordina IORT Technologies Developer of radiotherapy devices for cancer therapy | $3M | 49 mo ago | — | — | WordPress Block EditorElementorWordPress+24 | Funding Raised | 60 patents Image-guided radiotherapy devices and control systems for precise cancer treatment | — |
| 13 | T-ONE Therapeutics Developer of therapeutics for cancer treatment | $2M | 46 mo ago | — | Beatrice Bodega Founder | — | Seed | — | — |
| 14 | UBT Developer of microwave-based imaging diagnostic device for cancer | $2M | 58 mo ago | 14 | Gianluigi Tiberi Co-Founder | WordPressMySQLPHP+25 | Funding Raised | 11 patents Microwave dielectric sensing for material characterization and breast tissue integrity diagnostics | — |
| 15 | MolMed Developer of gene and cell therapies for the treatment of cancer and rare diseases | $2M | 114 mo ago | 223 | — | — | Acqui-Hired | — | — |
| 16 | METIS Precision Medicine Developer of immunotherapies for treating cancer | $1M | 91 mo ago | 4 | Mauro Brunelli CEO | — | Seed | — | — |
| 17 | Biogenera Developer of therapeutics for the treatment of cancer in pediatric patients | $1M | 145 mo ago | 16 | — | WordPressMySQLPHP+17 | Public | 25 patents Therapeutic antisense/siRNA oligonucleotides for targeted gene expression modulation | — |
| 18 | Exiris Developer of therapeutic agents for the treatment of oncology indications | $619K | 80 mo ago | — | Gessica Filocamo Co-Founder | — | Funding Raised | 17 patents Therapeutic monoclonal antibodies targeting FGFR4 for oncology applications. | — |
| 19 | Scent Screening device for colorectal adenomas | $346K | 85 mo ago | — | Cesare Malagu CEO | YouTubeNginxCloudflare+6 | Funding Raised | 2 patents Colorectal adenoma detection using optical screening devices | — |
| 20 | Exosomes Developer of exosomes in liquid biopsy | $310K | 102 mo ago | 7 | — | — | Funding Raised | — | — |
| 21 | Nerviano Medical Sciences Italian, clinical-stage oncology-focused drug discovery company | $198K | 98 mo ago | 400 | Luciano Baielli CEO & Director | WordPressPleskMySQL+18 | Acquired | 1,294 patents Small-molecule kinase inhibitors and antibody‑drug conjugate payloads for cancer therapy | — |
| 22 | Mirnagreen Developer of plant microRNA-based products | $111K | 79 mo ago | 7 | — | — | Funding Raised | 16 patents Extraction and purification of bioactive small RNAs from plant and mushroom sources | — |
Top 12 Oncology companies in Italy
#1
Seed · Turin, Piedmont · founded 2025$3.5Mraised▾
Developer of immunotherapies targeting genetically defined cancers for durable patient options. The company integrates targeted therapies with immune-based approaches for challenging tumors. It focuses on enhancing precision oncology by targeting resistance mechanisms and tumor adaptation. The company is advancing its lead KRAS G12C program and building scalable paths for next-generation therapies.
- Dec 2025Seed$3.5M
#2
Public · Milan, Lombardy · founded 2014 · 9 employees$33.6Mraised▾
Developer of lentivirus-based gene and cell therapies for cancer. The lead candidateTemferon is a lentivirus-based hematopoietic stem progenitor cell immuno-gene therapy for Glioblastoma, solid tumor, and hematological malignancies. Also, has Tie2-Expressing Monocytes immunotherapies for multiple cancer treatment.
- Mar 2025Post IPO$21.9M
- Sep 2019Series C$14.6M
- Sep 2017Series B$8M
- Mar 2015Series A$11M
#3
Series A · Milan, Lombardy · founded 2004 · 32 employees$15.8Mraised▾
Provider of automated solutions for in liquid biopsy. It offer a pre‑analytical workstation for blood samples at the collection siteand separates plasma and stabilizes cellular fraction directly on nanocoated SmartBioSurface microscope slides ideal for detecting circulating tumor cells (CTCs) and preserving cell-free plasma.
- Jan 2025PE$15.3M
- Aug 2018Grant (prize money)$58.4K
- May 2018Grant (prize money)$60K
- Jun 2016Grant (prize money)$340.2K
#4
Series A · Milano, Umbria · founded 2017 · 14 employees$18.9Mraised▾
Provider of a radiotherapy platform for the treatment of solid tumors. The company is involved in developing a proprietary medical device platform, and a proprietary drug delivery system. The medical device platform is based on the combination of radioactive glue, β-emitting radiotherapy, and external beam radiation therapy which is administered to patients suffering from several types of cancers.
- Jun 2024Series A$8.7M
- Jul 2022Series A$10.2M
#5
Acquired · Nerviano, Lombardy · founded 1965 · 1 employees$157.6Mraised▾
Developer of therapeutics for the treatment of cancer. The company develops innovative new chemical entities (NCE) for the treatment of cancers and its lead product is an oral inhibitor of IDH1 and IDH2, for solid tumors. Also, it develops Entrectinib, the kinase inhibitor drug as an antitumor therapy.
#6
Series A · Turin, Piedmont · founded 2023$7.6Mraised▾
Developer of cellular immunotherapies for ALK-positive cancers. The company is developing TCR-T to target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients.
- Dec 2023Series A$7.6M
#7
Series A · Trento, Trentino South Tyrol · founded 2017 · 14 employees$25.2Mraised▾
AI-powered platform for drug discovery. The company's approach, named "Pharmacological protein Inactivation by Folding Intermediates Targeting" (PPI-FIT), allows them to identify and develop small molecules acting on targets involved in different types of diseases. It's pipeline currently focuses on Cyclin D1 and KRAS as the main targets for oncology and inflammatory diseases.
- Oct 2022Series A$22.5M
- Oct 2019Seed$2.6M
#8
Public · Sovicille, Tuscany · founded 1996 · 157 employees$69.7Mraised▾
Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders. It offers bioactive agents such as cytokines and small molecule ligands directly to disease sites exploiting overexpressed antigens in angiogenesis related disorders such as cancer, rheumatoid arthritis, and AMD.
#9
Late Stage · Ancona, Marche · founded 1994 · 60 employees$3.2Mraised▾
Provider of diagnostic kits for pharmacogenetic tests. The company's test portfolio includes EasyPGX line of single-gene tests for cancer (using circulating DNA), Myriapod - an SNP panel for predicting adverse response to anticancer therapy, Easy line of kits that allow the qualitative detection of the main somatic mutations of the genes EGFR, KRAS, NRAS and BRAF by Real-Time PCR in association with a system of enrichment of the mutated allele, and the titan microsatellite instability test. The company is also developing the Leonid platform for transcript biomarker analysis of lung cancer.
- Apr 2023PE—
- Jun 2021PE—
- Dec 2016Grant (prize money)$1.8M
- Jul 2015Grant (prize money)$1.4M
#10
Series A · Alghero, Sardinia · founded 2007$13Mraised▾
ViroStatics is an Italian early-stage drug development company focusing on novel Cyclin-Dependent Kinase (CDK) inhibitors, which selectively target CDK4/6/9. They have a preclinical candidate for HIV, for which the IND was submitted in 2016. ViroStatics is a for-profit spin-off from the Research Institute for Human and Genetic Therapy (RIGHT).
- Jul 2017Grant (prize money)$58.8K
- Mar 2017Grant (prize money)$52.7K
- Jan 2017Grant (prize money)$52.1K
- 2007Series A$13M
#11
Seed · Milan, Lombardy · founded 2022$2.5Mraised▾
Developer of therapeutics for cancer treatment. It offers anticancer therapies that are focused on the regulation of the activation of T lymphocytes to a sequence of human DNA to kill cancer cells.
- Sep 2022Seed$2.5M
#12
Funding Raised · Vicenza, Veneto · founded 2013$2.6Mraised▾
Developer of radiotherapy devices for cancer therapy. The company offer products such as the LIAC HWL, a technology designed to minimize scatter radiation in operating rooms, and the NOVAC 11, a solid technology used for IOeRT treatments. The company is also involved in research and development in the field of FLASH radiotherapy for cancer treatment.
- Jun 2022Grant (prize money)$2.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Italy
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,610 Italy-affiliated papers.
- Istituti di Ricovero e Cura a Carattere Scientifico238
- Humanitas University86
- IRCCS Humanitas Research Hospital80
- Agostino Gemelli University Polyclinic78
- University of Milan77
- Tumor microenvironment14→146
- Immune system4→107
- Cancer research21→108
- Immunotherapy3→76
- Cancer immunotherapy2→39
- Tumor microenvironment25→342
- Immune system9→258
- Immunotherapy1→196
- Cancer research18→202
- Cancer cell2→40
- Tumor microenvironment10→125
- Immunotherapy1→114
- Immune system5→103
- Cancer research7→54
- Cancer immunotherapy1→44
Where oncology is researched across Italy
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.